Document Type

Article

Publication Date

11-4-2020

Identifier

DOI: 10.3390/antib9040060

Abstract

Intravenous immune globulin (IVIG) is made after processing plasma from healthy donors. It is composed mainly of pooled immunoglobulin and has clinical evidence-based applications in adult and pediatric populations. Recently, several clinical applications have been proposed for managing conditions in the neonatal population, such as hemolytic disease of the newborn, treatment, and prophylaxis for sepsis in high-risk neonates, enterovirus parvovirus and COVID-19 related neonatal infections, fetal and neonatal immune-induced thrombocytopenia, neonatal hemochromatosis, neonatal Kawasaki disease, and some types of immunodeficiency. The dosing, mechanism of action, effectiveness, side effects, and adverse reactions of IVIG have been relatively well studied in adults but are not well described in the neonatal population. This review aims to provide the most recent evidence and consensus guidelines about the use of IVIG in the fetus and neonate.

Journal Title

Antibodies (Basel)

Volume

9

Issue

4

Keywords

coronavirus; coronavirus disease 19 (COVID-19); fetus; hemolysis; hyperbilirubinemia; immunoglobulins; necrotizing enterocolitis; neonates; sepsis

Comments

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Publisher's Link:https://www.mdpi.com/2073-4468/9/4/60

Download

Included in

Pediatrics Commons

Share

COinS